First Business Financial Services Inc. Sells 150 Shares of Johnson & Johnson $JNJ

First Business Financial Services Inc. decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 2.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,214 shares of the company’s stock after selling 150 shares during the period. First Business Financial Services Inc.’s holdings in Johnson & Johnson were worth $796,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. GFG Capital LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth $35,000. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson in the first quarter worth $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson in the first quarter worth $48,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson in the first quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson in the first quarter worth $52,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $190.38 on Friday. The stock’s 50-day simple moving average is $182.26 and its 200-day simple moving average is $166.13. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48. The company has a market capitalization of $458.69 billion, a price-to-earnings ratio of 18.38, a PEG ratio of 2.26 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion for the quarter. As a group, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

Analyst Upgrades and Downgrades

JNJ has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. HSBC lifted their price objective on Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Thursday, October 16th. Sanford C. Bernstein lifted their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a report on Monday, October 6th. UBS Group lifted their target price on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research report on Tuesday, October 14th. Finally, Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $199.05.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.